Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

Regeneron Forward-Looking Statements and Use of Digital Media ... Atopic dermatitis is a chronic disease that disproportionately impacts communities of color.

Regeneron Pharmaceuticals (REGN) and Sanofi ... 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen.

Apogee Therapeutics said its antibody treatment alleviated signs and symptoms of atopic dermatitis far more than a placebo — ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. ... Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, ...

Regeneron Pharmaceuticals, Inc. Atopic dermatitis is a chronic disease that disproportionately impacts communities of color. Dupixent achieved 75% or greater improvement in overall disease ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

Regeneron Contacts: Media Relations Ilana Yellen Tel: +1 914-330-9618 [email protected] Sanofi Contacts: Media Relations Sandrine Guendoul Tel: +33 6 25 09 14 25 ...